This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
NVDA & PLTR Driving AI in Health: Top Health IT Stocks for Q3 Earnings
by Urmimala Biswas
NVDA and PLTR drive AI integration across healthcare, fueling optimism for Omnicell and Tempus AI's Q3 performance.
NVDAPositive Net Change OMCLNegative Net Change ORCLNegative Net Change PLTRPositive Net Change TEMPositive Net Change
artificial-intelligence earnings medical medical-devices robotics smart-health tech-stocks
Hims & Hers Gains 3.8% in 3 Months: Time to Hold the Stock or Sell?
by Debanjana Dey
HIMS expands into men's health and hormones, but rising costs and regulatory hurdles threaten its momentum.
TDOCNo Net Change AMWLNegative Net Change HIMSNegative Net Change
medical medical-devices
STXS Partners With CardioFocus to Boost Robotic Pulsed Field Ablation
by Zacks Equity Research
Stereotaxis partners with CardioFocus to commercialize the first robotic Pulsed Field Ablation system, aiming to revolutionize cardiac arrhythmia treatment.
MASINegative Net Change MMSIPositive Net Change STXSPositive Net Change WSTPositive Net Change
medical medical-devices
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
by Zacks Equity Research
Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.
ALNYNegative Net Change ALLONo Net Change CMMBPositive Net Change TVRDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?
by Sundeep Ganoria
ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.
JNJNegative Net Change LLYPositive Net Change ABBVNegative Net Change
earnings medical pharmaceuticals
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
by Ahan Chakraborty
CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.
PFEPositive Net Change AMPHNegative Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers stock slips below its 50-day average as generic pressure, high debt, and trimmed earnings outlook weigh on sentiment
BMYNegative Net Change PFEPositive Net Change MRKPositive Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals Stock?
by Zacks Equity Research
Investors need to pay close attention to BCRX stock based on the movements in the options market lately.
BCRXNegative Net Change
medical
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings
by Zacks Equity Research
DGX is poised for solid Q3 2025 results, backed by strong DIS growth, strategic M&A and robust test demand across key health segments.
DGXPositive Net Change IDXXNegative Net Change ANIPNegative Net Change EXASNegative Net Change
earnings medical medical-devices
HOLX's Enhanced Fibroid Treatment Portfolio Powers GYN Surgical Growth
by Moumi Mondal
Hologic's GYN Surgical segment gains momentum internationally as expanded fibroid treatments support growth.
JNJNegative Net Change MDTNegative Net Change HOLXNegative Net Change
medical medical-devices
Can ISRG Continue Its Strong Growth Amid Tariff & Rare Earth Woes?
by Indrajit Bandyopadhyay
ISRG's growth momentum faces pressure as tariffs and China's rare earth export curbs threaten margins and supply stability.
SYKNegative Net Change ISRGNegative Net Change GMEDNegative Net Change
medical medical-devices
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
by Zacks Equity Research
Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
BIIBNegative Net Change FOLDNegative Net Change CRMDPositive Net Change DNLINegative Net Change
biotechnology biotechs medical pharmaceuticals
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal
by Zacks Equity Research
PTGX shares jump 30% after reports that J&J is in talks to acquire the biotech firm amid ongoing negotiations.
RHHBYPositive Net Change JNJNegative Net Change PFEPositive Net Change PTGXNegative Net Change
biotechs medical pharmaceuticals
AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve
by Zacks Equity Research
AstraZeneca secures a three-year tariff break after striking a landmark U.S. deal to cut drug prices and expand its domestic manufacturing.
AZNPositive Net Change PFEPositive Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
BD Stock Down Despite Making Progress in the Treatment of PAD Lesions
by Zacks Equity Research
BDX advances PAD care with first patient enrolled in the XTRACT Registry using its dual-action Rotarex system.
BDXNegative Net Change RMDPositive Net Change MASINegative Net Change SOLVNegative Net Change
medical medical-devices
INSP Shares Down Despite Strong Clinical Data From Inspire V Trials
by Zacks Equity Research
Inspire Medical's Inspire V system shows strong safety, faster surgeries, and higher patient adherence in new trials.
MASINegative Net Change MMSIPositive Net Change WSTPositive Net Change INSPNegative Net Change
medical medical-devices
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain
by Zacks Equity Research
ZTS secures CVMP's positive opinion recommending the approval of Lenivia, a long-acting OA pain therapy for dogs, with the final decision expected in late 2025.
ADCTNegative Net Change ZTSNegative Net Change ALLONo Net Change CMMBPositive Net Change
biotechnology biotechs medical pharmaceuticals
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
by Zacks Equity Research
Teva secures FDA approval for Uzedy label expansion to treat adults with bipolar I disorder.
SNYPositive Net Change TEVAPositive Net Change ALLONo Net Change CMMBPositive Net Change
medical
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?
by Ekta Bagri
Bristol Myers' $1.5B buyout of Orbital Therapeutics expands its cell therapy reach with a next-gen in vivo CAR T candidate and advanced RNA platform.
NVSNegative Net Change BMYNegative Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Sell Stocks for Oct. 13th
by Zacks Equity Research
AYTU, ALK and CNM have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2025.
ALKNegative Net Change AYTUPositive Net Change CNMPositive Net Change
industrial-products medical transportation
CVS' Aetna Wins Big on 2026 MA Star Ratings: How to Play the Stock?
by Moumi Mondal
CVS' Aetna shines in 2026 Medicare Star Ratings, with more than 81% of members in four-star plans, fueling a 73.5% YTD stock surge and strong investor momentum.
UNHNegative Net Change HUMNegative Net Change CVSPositive Net Change
medical medical-devices
Pulse Biosciences Unveils Promising First-in-Human Data for nPulse
by Zacks Equity Research
PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.
EWPositive Net Change MASINegative Net Change PLSENegative Net Change NDRANegative Net Change
medical medical-devices
Beat the Market the Zacks Way: MariMed, Xeris Biopharma, Lam Research in Focus
by Santanu Roy
MariMed, Xeris Biopharma and Lam Research shine as Zacks' proven stock strategies continue to beat the market despite turmoil.
UNHNegative Net Change DGXPositive Net Change MUPositive Net Change TMOPositive Net Change LRCXPositive Net Change ORCLNegative Net Change IDCCPositive Net Change MTZPositive Net Change MEGNegative Net Change NOBLNegative Net Change XERSPositive Net Change STNENegative Net Change
business-services communications computers construction medical semiconductor
5 Value Picks to Ride Out US-China Trade Rift & Government Shutdown
by Rimmi Singhi
Amid U.S.-China tensions and the U.S. government shutdown, five high-earnings-yield value stocks stand out for long-term investors.
MUPositive Net Change STNENegative Net Change DINONegative Net Change FTRENegative Net Change AAUCPositive Net Change
gold internet medical oil-energy tech-stocks
Zacks.com featured highlights include StoneCo, Universal Health Services, Integer Holdings and Great Lakes Dredge & Dock
by Zacks Equity Research
Zacks highlights STNE, UHS, ITGR, and GLDD as value stocks with strong cash flow and growth potential amid earnings and government shutdown concerns.
UHSPositive Net Change GLDDPositive Net Change ITGRNegative Net Change STNENegative Net Change
medical